|Bid||0.00 x 1100|
|Ask||0.00 x 3100|
|Day's Range||20.80 - 21.66|
|52 Week Range||15.68 - 29.49|
|Beta (3Y Monthly)||1.42|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Heron Therapeutics (HRTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Last week saw the newest third-quarter earnings release from Heron Therapeutics, Inc. (NASDAQ:HRTX), an important...
Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the Jefferies London Healthcare Conference on Thursday, November 21, 2019 at 5:20 p.m. GMT (12:20 p.m. EST) at the Waldorf Hilton London hotel.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 30.00% and 25.64%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The biotech sector has not been nearly as strong and is still off around 10% from the highs hit earlier in the year, as seen in the SPDR S&P Biotech ETF . TG Therapeutics should file another NDA for the treatment of Chronic Lymphocytic Leukemia, or CLL, in combination with its other late-stage compound TG-1101 sometime in the first half of 2020.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Anyone researching Heron Therapeutics, Inc. (NASDAQ:HRTX) might want to consider the historical volatility of the...
Study results show 75% of knee-replacement patients were discharged from the hospital without a prescription for opioids.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...
You should never blindly follow the crowd, but it pays to watch what the biggest and brightest on Wall Street are doing.
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 7.35% and 18.11%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a stock with outstanding fundamental characteristics. When we build an...
Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that's why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […]
The last three months have been tough on Heron Therapeutics, Inc. (NASDAQ:HRTX) shareholders, who have seen the share...
Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -70.21% and 15.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?